The University of Connecticut’s athletic department will host four separate bone marrow registry drives throughout November.

A donut-eating contest helped raise funds for 17-year-old Levi Atkins, who's battling Acute Myeloid Leukemia, while uniting ...

Brisa Aschebrook-Kilfoy, Associate Professor of Family Medicine at UChicago, is an expert in conducting environmental exposure assessments. She is actively leading efforts to build resources to study ...

Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...

The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...

The US Food and Drug Administration has approved revumenib (Revuforj — Syndax Pharmaceuticals) for relapsed or refractory ...

Lea Ann Ragusin Photography At Texas Children's Hospital, Fivecoat's daughter Shelly McAfee and her husband Tyler McAfee were ...

Moleculin Biotech (MBRX) announced new findings supporting the ability of Annamycin to overcome resistance to Venetoclax in acute myeloid leukemia. This includes data from preclinical in vitro studies ...

Relapsed or refractory acute leukemia with a KMT2A translocation currently has an overall survival rate of less than one year when treated with frontline therapies. Syndax Pharmaceuticals recently ...

A grandmother, diagnosed with breast cancer, and her toddler granddaughter, diagnosed with acute myeloid leukemia, are facing ...

In the AUGMENT-101 trial, 21 percent of patients achieved complete remission plus complete remission with partial hematological recovery on the drug.

Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute ...